Drug Index

Pegfilgrastim

 
print

Mechanism :

Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase


Indication :

• Acute leukemia receiving induction or consolidation chemotherapy


Contraindications :

Pegfilgrastim is contraindicated in conditions like Hypersensitivity to the drug.


Dosing :

1 to 12 years: 0.1 mg/kg SC (Maximum dose: 6 mg) once per chemotherapy cycle, beginning 24 to 72 hours after completion of chemotherapy.

13 to 18 years, >45 kg: 6 mg once per chemotherapy cycle, beginning 24 to 72 hours after completion of chemotherapy.


Adverse Effect :

Bone pain, allergic reactions, Respiratory distress syndrome, myalgia, arthralgia, leucocytosis.


Interaction :

Drug Interactions Not Available.


07/14/2019 06:54:41 Pegfilgrastim
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0